Julie S. Torode/X
Apr 6, 2025, 06:30
Julie S. Torode: WHO Prequalifies Alinity m HR HPV Assay by Abbott for Cervical Cancer Screening and Prevention
Julie S. Torode, Director of Strategic Partnerships, Patient and Community Engagement of Institute of Cancer Policy at King’s College London, shared on LinkedIn:
“Fabulously see a new HPV assay is prequalified by WHO adding Alinity m HR HPV manufactured by Abbott for the detextion if 14 HPV types for cervical cancer screening and prevention.
Our recent report from an expert roundtable in Geneva called for WHO to focus on a pooled procurement process to support high burden countries in purchasing the right equipment and commodities for pillar 2 – screening and treatment of precancerous lesions: HPV tests; self collection kits; thermal ablation and LEEP units. This will surely also encourage other manufacturers to prequalify.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 6, 2025, 06:41
Apr 6, 2025, 06:32
Apr 6, 2025, 06:18
Apr 6, 2025, 06:01
Apr 6, 2025, 05:46